Gynaecology — MCQs
On this page
A 30-year-old woman presents with 5 weeks amenorrhoea and minimal vaginal spotting. Transvaginal ultrasound shows an empty uterus and a 2.5 cm adnexal mass adjacent to the right ovary with a hyperechoic ring. There is no free fluid in the pouch of Douglas. Her serum beta-hCG is 2200 IU/L. She is haemodynamically stable and reports mild right-sided pelvic discomfort. What is the most appropriate initial management?
What is the minimum fall in serum beta-hCG expected between days 0 and 7 following successful treatment of ectopic pregnancy with a single dose of intramuscular methotrexate?
A 43-year-old woman presents with heavy menstrual bleeding and is found to have a haemoglobin of 87 g/L. Transvaginal ultrasound reveals a 7 cm intramural fibroid and an endometrial thickness of 6 mm on day 4 of her cycle. She wishes to preserve her fertility. Which treatment option is most likely to preserve fertility while effectively managing her symptoms?
A 36-year-old woman is being monitored for a tubal ectopic pregnancy with expectant management. Her initial serum beta-hCG was 450 IU/L. She is clinically stable with minimal pain and no vaginal bleeding. A repeat beta-hCG measurement 48 hours later shows a level of 520 IU/L. What is the most appropriate next step in management?
A 25-year-old woman attends her GP with a 3-month history of intermenstrual bleeding. She has been taking the combined oral contraceptive pill reliably for 2 years. She is sexually active with one partner and reports no dyspareunia or pelvic pain. Speculum examination shows a healthy-looking cervix with no visible lesions. What is the most appropriate next investigation?
A 41-year-old multiparous woman presents with increasingly heavy menstrual bleeding over the past year. Her periods last 9 days and she passes large clots. Her haemoglobin is 98 g/L. She has completed her family and desires definitive treatment. Transvaginal ultrasound shows a uniformly enlarged uterus measuring 14 cm with no focal lesions and an endometrial thickness of 8 mm on day 5 of her cycle. What is the most appropriate definitive management option?
A 40-year-old woman with heavy menstrual bleeding has been treated with tranexamic acid for 6 months with partial improvement. She is currently using condoms for contraception and has completed her family. Her uterus is normal size on examination and transvaginal ultrasound shows no structural abnormalities with endometrial thickness of 8mm. Her haemoglobin is 108 g/L. She declines hormonal treatments. What is the most appropriate next management step?
A 31-year-old woman presents with sudden onset left-sided pelvic pain. She has had IVF treatment and is 7 weeks pregnant with a singleton intrauterine pregnancy confirmed on scan 5 days ago. Today's transvaginal ultrasound shows the viable intrauterine pregnancy and a new 35mm left adnexal complex mass. Beta-hCG is 48,000 IU/L. She is haemodynamically stable. Free fluid is present in the pelvis. What is the most likely diagnosis?
A 48-year-old woman presents with menorrhagia and dysmenorrhoea. Transvaginal ultrasound shows a bulky uterus with asymmetrical myometrial thickening and small myometrial cysts. The endometrium is 7mm thick. What is the most likely diagnosis?
A 29-year-old woman is diagnosed with a tubal ectopic pregnancy. Serum beta-hCG is 2,800 IU/L. She is clinically stable with minimal pain. The ectopic mass measures 38 mm on transvaginal ultrasound with no visible fetal heartbeat. She has no contraindications to medical management and strongly wishes to avoid surgery. What is the most appropriate management?
Gynaecology UK Medical PG Practice Questions and MCQs
Question 121: A 30-year-old woman presents with 5 weeks amenorrhoea and minimal vaginal spotting. Transvaginal ultrasound shows an empty uterus and a 2.5 cm adnexal mass adjacent to the right ovary with a hyperechoic ring. There is no free fluid in the pouch of Douglas. Her serum beta-hCG is 2200 IU/L. She is haemodynamically stable and reports mild right-sided pelvic discomfort. What is the most appropriate initial management?
- A. Repeat beta-hCG in 48 hours to confirm ectopic pregnancy
- B. Emergency laparoscopic salpingectomy
- C. Administer intramuscular methotrexate (Correct Answer)
- D. Expectant management with weekly beta-hCG monitoring
- E. Diagnostic laparoscopy to confirm diagnosis
Explanation: ***Administer intramuscular methotrexate*** - The patient is **haemodynamically stable** with a serum **beta-hCG <5000 IU/L** (2200 IU/L) and an adnexal mass **<3.5 cm** (2.5 cm) without a fetal heartbeat, which are the primary criteria for medical management of ectopic pregnancy. - **Methotrexate** is a folic acid antagonist that stops the growth of the trophoblastic tissue, leading to the resolution of the ectopic pregnancy and often preserving the fallopian tube, avoiding surgical risks. *Repeat beta-hCG in 48 hours to confirm ectopic pregnancy* - Repeating the beta-hCG is unnecessary because the current **beta-hCG is above the discriminatory zone** (>1500-2000 IU/L) and **transvaginal ultrasound** has already confirmed an **adnexal mass** and **empty uterus**, strongly indicative of ectopic pregnancy. - Delaying definitive treatment for a confirmed ectopic pregnancy increases the risk of **tubal rupture** and significant hemorrhage, especially with a beta-hCG of 2200 IU/L. *Emergency laparoscopic salpingectomy* - Surgical intervention like **laparoscopic salpingectomy** is typically reserved for patients who are **haemodynamically unstable**, experiencing severe pain, or have signs of **tubal rupture** (e.g., free fluid in the pouch of Douglas, larger mass). - This patient is stable with a small, unruptured ectopic pregnancy, making medical management a suitable and less invasive initial approach that also helps **preserve fertility**. *Expectant management with weekly beta-hCG monitoring* - **Expectant management** is generally considered only when initial **beta-hCG levels are very low (<1000-1500 IU/L)** and are already declining spontaneously, with no fetal cardiac activity or significant adnexal mass. - With a beta-hCG of **2200 IU/L**, the risk of rupture is too high to simply monitor without active medical or surgical intervention; it falls outside the accepted criteria for expectant management. *Diagnostic laparoscopy to confirm diagnosis* - **Diagnostic laparoscopy** is an invasive surgical procedure that is not required in this case, as the diagnosis of ectopic pregnancy is clearly established by the combination of **transvaginal ultrasound findings** (empty uterus, adnexal mass with hyperechoic ring) and the **serum beta-hCG level**. - Modern imaging and biochemical markers are usually sufficient for diagnosis, and proceeding directly to medical treatment avoids unnecessary surgical risks and costs.
Question 122: What is the minimum fall in serum beta-hCG expected between days 0 and 7 following successful treatment of ectopic pregnancy with a single dose of intramuscular methotrexate?
- A. At least 10% decrease from day 0 to day 7
- B. At least 15% decrease from day 4 to day 7 (Correct Answer)
- C. At least 25% decrease from day 0 to day 7
- D. At least 50% decrease from day 0 to day 7
- E. Return to undetectable levels by day 7
Explanation: ***At least 15% decrease from day 4 to day 7*** - In the single-dose **methotrexate** protocol for ectopic pregnancy, success is defined by a decrease of **15% or more** in **beta-hCG** levels between **day 4 and day 7**. - This specific measurement interval is used because hCG levels often **initially rise** between day 0 (day of administration) and day 4 due to the drug's mechanism of action. *At least 10% decrease from day 0 to day 7* - This is an incorrect threshold; clinical protocols specifically require a **15% drop** to determine if the medical management is effective. - Measuring the percentage decrease from **day 0** is unreliable because hCG levels commonly **increase** in the first **96 hours** (up to day 4) after methotrexate administration. *At least 25% decrease from day 0 to day 7* - While a greater drop is desirable for a faster resolution, a **15% reduction** between day 4 and 7 is the established minimum criterion for initial success with a single dose to avoid a **second dose** or surgical intervention. - As previously mentioned, measuring from **day 0** is not the standard for initial assessment of success due to the potential for an initial rise in hCG. *At least 50% decrease from day 0 to day 7* - A **50% decrease** in beta-hCG is not the specific criterion for assessing successful single-dose methotrexate treatment within the first week, and it's an overly ambitious expectation for this timeframe. - If the **15% drop** between day 4 and 7 is not met, further management, such as a **second dose of methotrexate** or **surgical intervention**, is usually considered. *Return to undetectable levels by day 7* - It is physiologically impossible for **beta-hCG** to reach **undetectable levels** (typically <5 IU/L) within just one week of initiating methotrexate treatment for ectopic pregnancy. - Complete resolution and a return to undetectable hCG levels usually take **2 to 8 weeks**, requiring consistent **weekly follow-up** until the hormone is fully cleared.
Question 123: A 43-year-old woman presents with heavy menstrual bleeding and is found to have a haemoglobin of 87 g/L. Transvaginal ultrasound reveals a 7 cm intramural fibroid and an endometrial thickness of 6 mm on day 4 of her cycle. She wishes to preserve her fertility. Which treatment option is most likely to preserve fertility while effectively managing her symptoms?
- A. Levonorgestrel-releasing intrauterine system
- B. Uterine artery embolisation
- C. Myomectomy (Correct Answer)
- D. Ulipristal acetate
- E. Gonadotropin-releasing hormone agonist
Explanation: ***Myomectomy***- **Myomectomy** is the gold standard surgical intervention for **symptomatic fibroids** in patients who wish to **preserve fertility**, as it removes the leiomyoma while keeping the uterus intact.- For a large **7 cm intramural fibroid** causing severe **anaemia**, this procedure effectively resolves mechanical and bleeding symptoms while maintaining the potential for future pregnancy.*Levonorgestrel-releasing intrauterine system*- While the **LNG-IUS** is first-line for heavy menstrual bleeding, its efficacy and retention are significantly reduced in the presence of a large **intramural fibroid** exceeding 3 cm.- Significant **uterine distortion** by large fibroids can make the insertion technically difficult and increases the risk of **expulsion**.*Uterine artery embolisation*- **UAE** is a minimally invasive treatment for fibroids but is generally **not recommended** for women primary wishing to **conceive** due to potential risks to placental blood flow.- It has been associated with an increased risk of **miscarriage**, preterm birth, and potential impairment of **ovarian reserve**.*Ulipristal acetate*- This selective progesterone receptor modulator was used for fibroid management but is now restricted or **withdrawn** in many regions due to the risk of rare but serious **hepatotoxicity**.- Even when used, it is typically a short-term management option rather than a definitive treatment for high-volume fibroid disease.*Gonadotropin-releasing hormone agonist*- **GnRH agonists** are primarily used as **pre-operative** therapy to reduce fibroid volume and improve **haemoglobin levels** before surgery.- They are not a long-term fertility-preserving solution because symptoms and fibroid size rapidly **recur** once the medication is discontinued.
Question 124: A 36-year-old woman is being monitored for a tubal ectopic pregnancy with expectant management. Her initial serum beta-hCG was 450 IU/L. She is clinically stable with minimal pain and no vaginal bleeding. A repeat beta-hCG measurement 48 hours later shows a level of 520 IU/L. What is the most appropriate next step in management?
- A. Continue expectant management and repeat beta-hCG in 48 hours
- B. Administer intramuscular methotrexate (Correct Answer)
- C. Arrange transvaginal ultrasound scan
- D. Discharge with safety-netting advice
- E. Arrange urgent laparoscopic salpingectomy
Explanation: ***Administer intramuscular methotrexate*** - The patient's **beta-hCG has risen** from 450 to 520 IU/L, indicating the ectopic pregnancy is not resolving spontaneously, thus failing the criteria for continued **expectant management**.- **Methotrexate** is the appropriate medical treatment for a **clinically stable** patient with an **unruptured ectopic pregnancy** and rising or plateauing beta-hCG levels, especially when the initial level is below 3000-5000 IU/L.*Continue expectant management and repeat beta-hCG in 48 hours*- **Expectant management** is only suitable for ectopic pregnancies when **beta-hCG levels are low and spontaneously declining**, signifying resolution.- Continuing expectant management despite rising beta-hCG levels increases the risk of **tubal rupture** and severe complications, requiring prompt intervention.*Arrange transvaginal ultrasound scan*- While **transvaginal ultrasound** is crucial for diagnosing an ectopic pregnancy, the diagnosis is already established, and the rising **beta-hCG** biochemically confirms ongoing active trophoblastic growth.- A repeat ultrasound at this stage would not change the immediate need for intervention, as the biochemical trend already dictates the change in management.*Discharge with safety-netting advice*- Discharging a patient with an **actively growing ectopic pregnancy** (indicated by rising hCG) is unsafe and could lead to severe, life-threatening complications such as **tubal rupture** and hemorrhage.- Active medical intervention is required, not passive observation, to manage the progression of the ectopic pregnancy safely.*Arrange urgent laparoscopic salpingectomy*- **Surgical management** like **laparoscopic salpingectomy** is usually reserved for patients who are **hemodynamically unstable**, have severe pain, show signs of rupture, or have high beta-hCG levels (typically >5000 IU/L).- Given that the patient is **clinically stable** with minimal pain and a relatively low beta-hCG, **methotrexate** offers a less invasive and appropriate first-line treatment.
Question 125: A 25-year-old woman attends her GP with a 3-month history of intermenstrual bleeding. She has been taking the combined oral contraceptive pill reliably for 2 years. She is sexually active with one partner and reports no dyspareunia or pelvic pain. Speculum examination shows a healthy-looking cervix with no visible lesions. What is the most appropriate next investigation?
- A. Transvaginal ultrasound scan
- B. Cervical smear test if due
- C. Endometrial biopsy
- D. High vaginal and endocervical swabs for infection screen (Correct Answer)
- E. Serum follicle-stimulating hormone and luteinising hormone levels
Explanation: ***High vaginal and endocervical swabs for infection screen***- In a young, sexually active woman presenting with **intermenstrual bleeding**, the most appropriate initial step is to exclude a **Sexually Transmitted Infection (STI)** such as **Chlamydia trachomatis**, which is a common cause of cervicitis and irregular bleeding.- Despite a healthy-looking cervix and no other symptoms like **pelvic pain** or **dyspareunia**, **STI screening** is paramount before considering more invasive or complex investigations. *Transvaginal ultrasound scan*- This investigation is primarily used to identify **structural abnormalities** such as **fibroids**, **polyps**, or assess **endometrial thickness**.- It is not the first-line investigation in a young woman with a normal speculum exam, as infectious causes are more prevalent in this demographic and should be ruled out first. *Cervical smear test if due*- A **cervical smear test** is a screening tool for **cervical pre-malignant** and **malignant changes**, not a diagnostic tool for acute symptomatic bleeding.- While important for routine health, it does not directly address the immediate cause of **intermenstrual bleeding** and does not replace the need for an **infection screen**. *Endometrial biopsy*- This invasive procedure is typically reserved for women **over 45 years old** or those with significant risk factors for **endometrial hyperplasia** or **malignancy**, especially in cases of persistent abnormal uterine bleeding.- In a 25-year-old woman on the **combined oral contraceptive pill (COCP)**, the risk of endometrial pathology is very low, making this an inappropriate initial investigation. *Serum follicle-stimulating hormone and luteinising hormone levels*- These hormone levels are assessed to investigate conditions related to **ovarian function**, such as **amenorrhea**, **infertility**, or suspected **menopause**.- The patient is reliably taking the **combined oral contraceptive pill**, which **suppresses endogenous FSH and LH production**, rendering these test results uninformative in this context.
Question 126: A 41-year-old multiparous woman presents with increasingly heavy menstrual bleeding over the past year. Her periods last 9 days and she passes large clots. Her haemoglobin is 98 g/L. She has completed her family and desires definitive treatment. Transvaginal ultrasound shows a uniformly enlarged uterus measuring 14 cm with no focal lesions and an endometrial thickness of 8 mm on day 5 of her cycle. What is the most appropriate definitive management option?
- A. Levonorgestrel-releasing intrauterine system
- B. Endometrial ablation
- C. Total hysterectomy (Correct Answer)
- D. Uterine artery embolisation
- E. Combined oral contraceptive pill
Explanation: ***Total hysterectomy*** - A **total hysterectomy** is the only **definitive treatment** for symptomatic **adenomyosis**, which is strongly suggested by a **uniformly enlarged uterus** (14 cm) with heavy menstrual bleeding and no focal lesions. - Since the patient has **completed her family** and specifically desires a permanent solution for her **anemia** (Hb 98 g/L) and severe symptoms, this surgical option offers a complete and lasting cure. *Levonorgestrel-releasing intrauterine system* - While the **LNG-IUS (Mirena)** is an effective first-line medical management for **heavy menstrual bleeding**, it is not considered **definitive** as symptoms can recur if removed or if it fails. - Its efficacy can be reduced in a significantly **enlarged uterus** (14 cm), potentially leading to a higher risk of **displacement** or expulsion and inadequate symptom control. *Endometrial ablation* - **Endometrial ablation** is generally unsuccessful in **adenomyosis** because the disease involves the deep **myometrium**, which ablation techniques cannot adequately reach or treat. - It is often contraindicated or less effective when the **uterine cavity** length or overall uterine size is significantly increased, such as in this case with a 14 cm uterus. *Uterine artery embolisation* - **Uterine artery embolisation (UAE)** is primarily indicated for **uterine fibroids**; while it can be used for adenomyosis, success rates for long-term symptom relief are lower and less predictable compared to hysterectomy. - UAE is a uterine-sparing procedure and does not provide the **definitive surgical cure** that the patient is requesting, particularly given her completed family. *Combined oral contraceptive pill* - The **COCP** offers hormonal management for menstrual bleeding but is not a **definitive treatment** and does not address the underlying **adenomyosis pathology** in a permanent way. - It is unlikely to provide sufficient and lasting symptom control for a patient with **significant anemia** and severe bleeding, especially when a definitive solution is desired.
Question 127: A 40-year-old woman with heavy menstrual bleeding has been treated with tranexamic acid for 6 months with partial improvement. She is currently using condoms for contraception and has completed her family. Her uterus is normal size on examination and transvaginal ultrasound shows no structural abnormalities with endometrial thickness of 8mm. Her haemoglobin is 108 g/L. She declines hormonal treatments. What is the most appropriate next management step?
- A. Increase dose of tranexamic acid
- B. Arrange hysteroscopy
- C. Refer for endometrial ablation (Correct Answer)
- D. Refer for hysterectomy
- E. Prescribe mefenamic acid
Explanation: ***Refer for endometrial ablation*** - This patient has failed **medical management** with non-hormonal agents (tranexamic acid) and has **declined hormonal treatments**, making a surgical intervention the appropriate next step. - **Endometrial ablation** is suitable as she has **completed her family**, has a normal-sized uterus with no structural abnormalities on ultrasound, and is a less invasive option than hysterectomy. *Increase dose of tranexamic acid* - She has already undergone a **6-month trial** with only partial improvement, indicating that increasing the dose is unlikely to provide adequate symptom control or resolve her **anaemia**. - Moving to a more definitive intervention is warranted given the failure of sustained improvement with current medical therapy. *Arrange hysteroscopy* - A **transvaginal ultrasound** has already shown a **normal uterus** with no structural abnormalities and an 8mm endometrial thickness, making significant focal intrauterine pathology unlikely. - **Hysteroscopy** is generally indicated when ultrasound is inconclusive or there's a high suspicion of a focal lesion not identified by imaging, which is not the case here. *Refer for hysterectomy* - While **hysterectomy** is a definitive cure for heavy menstrual bleeding, it is a **major surgical procedure** with associated higher risks and longer recovery compared to endometrial ablation. - Given the absence of structural pathology and her completed family, **less invasive surgical options** like ablation should be considered first before proceeding to hysterectomy. *Prescribe mefenamic acid* - **Mefenamic acid** is another non-hormonal medical treatment for heavy menstrual bleeding, often used alongside or instead of tranexamic acid. - However, the patient has already shown **partial improvement only** with 6 months of tranexamic acid, making it unlikely that another medical agent alone will provide sufficient relief or address her **anaemia**.
Question 128: A 31-year-old woman presents with sudden onset left-sided pelvic pain. She has had IVF treatment and is 7 weeks pregnant with a singleton intrauterine pregnancy confirmed on scan 5 days ago. Today's transvaginal ultrasound shows the viable intrauterine pregnancy and a new 35mm left adnexal complex mass. Beta-hCG is 48,000 IU/L. She is haemodynamically stable. Free fluid is present in the pelvis. What is the most likely diagnosis?
- A. Corpus luteum cyst rupture
- B. Ovarian torsion
- C. Heterotopic pregnancy (Correct Answer)
- D. Tubo-ovarian abscess
- E. Haemorrhagic ovarian cyst
Explanation: ***Heterotopic pregnancy*** - This patient's history of **IVF treatment** significantly increases the risk of **heterotopic pregnancy** (simultaneous intrauterine and ectopic pregnancies), which explains the **viable intrauterine pregnancy** and the **new 35mm left adnexal complex mass**. - The sudden onset of **pelvic pain** along with the **adnexal mass** and **free fluid** suggests rupture of the ectopic component, which is a common presentation of heterotopic pregnancy. *Corpus luteum cyst rupture* - While corpus luteum cysts are common in early pregnancy and can rupture causing pain and free fluid, the presence of a distinct **new 35mm complex adnexal mass** in the context of IVF strongly points towards an ectopic component rather than a simple cyst rupture. - A ruptured corpus luteum cyst often shows a collapsing or irregular cyst rather than a well-defined complex mass, and while it causes symptoms, the IVF history raises the suspicion for heterotopic pregnancy higher. *Ovarian torsion* - Ovarian torsion typically presents with **severe, acute pain** but classic ultrasound findings include an **enlarged, edematous ovary** and often altered or absent Doppler flow, rather than a discrete complex mass. - While severe pain is present, the specific description of a **new complex mass** alongside a confirmed intrauterine pregnancy makes heterotopic pregnancy a more direct fit given the significant risk factor of IVF. *Tubo-ovarian abscess* - Tubo-ovarian abscess (TOA) is an inflammatory process usually associated with **pelvic inflammatory disease (PID)**, and typically presents with fever, elevated inflammatory markers, and possibly vaginal discharge, none of which are mentioned here. - The patient is described as **haemodynamically stable** and lacks systemic signs of infection, making TOA an unlikely diagnosis in this early pregnancy. *Haemorrhagic ovarian cyst* - Haemorrhagic ovarian cysts can present as complex masses and cause pain, often showing a characteristic **reticular internal echo pattern** on ultrasound. - However, the combination of **IVF treatment**, a confirmed **intrauterine pregnancy**, and a **new adnexal complex mass** with **free fluid** necessitates a higher suspicion for **heterotopic pregnancy** due to its potentially life-threatening nature if ruptured.
Question 129: A 48-year-old woman presents with menorrhagia and dysmenorrhoea. Transvaginal ultrasound shows a bulky uterus with asymmetrical myometrial thickening and small myometrial cysts. The endometrium is 7mm thick. What is the most likely diagnosis?
- A. Endometrial hyperplasia
- B. Adenomyosis (Correct Answer)
- C. Multiple small fibroids
- D. Endometrial polyp
- E. Endometrial carcinoma
Explanation: ***Adenomyosis***- Characteristic ultrasound findings include an **asymmetrically thickened myometrium**, a **bulky uterus**, and the presence of **small myometrial cysts**, which represent ectopic endometrial tissue.- It classically presents in multiparous women in their 40s with a triad of **menorrhagia**, **dysmenorrhea**, and a **globular, tender uterus** on examination.*Endometrial hyperplasia*- This condition is primarily characterized by **excessive proliferation** of the endometrial glands, resulting in an **endometrial thickness** usually exceeding normal limits (e.g., >14mm in premenopausal women).- It does not cause **myometrial cysts** or **asymmetrical myometrial thickening**, as the pathology is confined to the uterine lining.*Multiple small fibroids*- Fibroids (leiomyomas) appear as **discrete, well-circumscribed, hypoechoic masses** on ultrasound, often with posterior acoustic shadowing.- While they cause a bulky uterus, they lack the **diffuse, cystic appearance** within the myometrium that is seen in adenomyosis.*Endometrial polyp*- A polyp is a **focal overgrowth** of the endometrial stroma and glands that projects into the **uterine cavity**.- Ultrasound usually identifies a polyp as a **hyperechoic lesion** within the endometrium, often with a visible **vascular feeding vessel** on Doppler, rather than myometrial changes.*Endometrial carcinoma*- This malignancy typically presents as **irregular endometrial thickening** or a focal mass, often associated with a disrupted endo-myometrial junction.- The **7mm endometrial thickness** in this premenopausal patient is within normal limits and the symptoms are better explained by the **myometrial pathology**.
Question 130: A 29-year-old woman is diagnosed with a tubal ectopic pregnancy. Serum beta-hCG is 2,800 IU/L. She is clinically stable with minimal pain. The ectopic mass measures 38 mm on transvaginal ultrasound with no visible fetal heartbeat. She has no contraindications to medical management and strongly wishes to avoid surgery. What is the most appropriate management?
- A. Administer single-dose methotrexate regimen
- B. Administer two-dose methotrexate regimen
- C. Recommend laparoscopic salpingotomy (Correct Answer)
- D. Recommend expectant management
- E. Administer multi-dose methotrexate regimen
Explanation: ***Recommend laparoscopic salpingotomy***- Medical management with methotrexate is generally reserved for ectopic masses **<35 mm**; since this mass is **38 mm**, surgical intervention is the preferred definitive treatment.- **Salpingotomy** (preserving the tube) is appropriate for women who wish to maintain future fertility, provided the contralateral tube is healthy and the patient is **haemodynamically stable**.*Administer single-dose methotrexate regimen*- The **mass size of 38 mm** exceeds the commonly accepted threshold of **35 mm**, which significantly increases the risk of therapy failure and **tubal rupture**.- While her **beta-hCG** is within the treatable range (<5,000 IU/L), the size of the adnexal mass makes medical management less reliable.*Administer two-dose methotrexate regimen*- Two-dose regimens are sometimes used for higher hCG levels, but they do not mitigate the physical risk associated with an **ectopic mass diameter** exceeding **35 mm**.- Failure rates and the risk of **emergency surgery** remain higher when the initial mass size is large, regardless of the dose count.*Recommend expectant management*- This approach is only considered when **beta-hCG** levels are very low (typically **<1,500 IU/L**) and demonstrably **declining**.- With an hCG of **2,800 IU/L** and a large mass, the risk of rupture is too high to justify monitoring without active intervention.*Administer multi-dose methotrexate regimen*- **Multi-dose methotrexate** involves more side effects and is typically reserved for complex cases or specific hCG protocols, not to overcome **mass size** contraindications.- Consistent with other medical options, the **38 mm size** remains the primary factor necessitating a recommendation for **surgical management**.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free